Abstract | AIMS: METHODS: twenty-two chemotherapy-naive patients with NSCLC (median age of 57 years, stage III-IV disease with metastases only in the thoracic region, Karnofsky index >60), received two cycles of regional plus systemic chemotherapy with a treatment-free interval of 4 weeks. The cytostatic regimen consisted of 10 mg/m(2) mitomycin, 25 mg/m(2) navelbine and 30 mg/m(2) cisplatin during ITP followed by low-dose systemic chemotherapy with 250 mg/m(2) 5-fluorouracil and 20 mg/m(2) cisplatin given as a continuous infusion on day 1-4. Patients were re-evaluated for response and surgery was carried out if possible. RESULTS: All 22 patients could be assessed for toxicity, response and survival. There were 19/22 remissions corresponding to a regression rate of 86.4%; 16/22 patients could be resected. This corresponded to a resectability rate of 72.7% (13 complete resections R0, 1 R1, 2 R2). Side-effects were transient and acceptable with no treatment- or surgery-related deaths. Median survival has not been reached after an observation time of 15 months. The estimated 1-year survival rate was 67.3%. CONCLUSIONS: Regional chemotherapy using an ITP application form is highly effective in advanced NSCLC stage III-IV leading to a high rate of resectability with an encouraging survival outcome.
|
Authors | H Müller |
Journal | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
(Eur J Surg Oncol)
Vol. 28
Issue 2
Pg. 165-71
(Mar 2002)
ISSN: 0748-7983 [Print] England |
PMID | 11884052
(Publication Type: Clinical Trial, Journal Article)
|
Copyright | Copyright Harcourt Publishers Limited. |
Chemical References |
- Mitomycin
- Vinblastine
- Cisplatin
- Vinorelbine
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, mortality, pathology, secondary)
- Chemotherapy, Cancer, Regional Perfusion
- Cisplatin
(administration & dosage, adverse effects)
- Combined Modality Therapy
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Humans
- Lung Neoplasms
(drug therapy, mortality, pathology)
- Male
- Middle Aged
- Mitomycin
(administration & dosage, adverse effects)
- Neoplasm Staging
- Palliative Care
(methods)
- Prognosis
- Survival Analysis
- Terminally Ill
- Treatment Outcome
- Vinblastine
(administration & dosage, adverse effects, analogs & derivatives)
- Vinorelbine
|